

## REMARKS

In response to the restriction requirement under 35 USC 121 and 372, Applicants elect the claims of Group I, claims 10-18, for initial prosecution. In response to the requirement for an election of species, Applicants elect 1-(chloroanilino)-4-(4-pyridylmethyl)phthalazine (PTK787), which is disclosed on page 38 of the specification as the single VEGF inhibitor and a histone deacylase inhibitor, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methylphenyl]-2E-2-propeneamide (LBH589), which is disclosed on page 11 of the specification, as the other chemotherapeutic agent.

Claims 10, 11, 12, 13, 14, 15, 16, 17 and 18 read on the elected invention.

Entry of this response is requested and an action on the merits is awaited.

Respectfully submitted,



George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824

Date: December 17, 2008